Form 4: Patrick Y. Yang Acquires Stock Options in Sana Biotechnology

Director Patrick Y. Yang reports acquisition of stock options in Sana Biotechnology.

Summary

• Patrick Y. Yang, a director of Sana Biotechnology, Inc. [SANA], reported the acquisition of stock options on June 6, 2024.
• The transaction involved the acquisition of 54,278 stock options with an exercise price of $7.36.
• These options vest on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana.
• Following the reported transaction, Yang directly owns 54,278 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continuous service to Sana Biotechnology through the vesting date, suggesting an expectation of continued involvement by the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates